Literature DB >> 26884839

Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy.

Cong Wang1, Qian Li1, Junhui Zhen2, Yihuai Xu1, Shuzhen Sun1.   

Abstract

AIMS: To investigate the roles of CXCL16 and ox-LDL in adriamycin (ADR)-induced nephropathy mice and to explore the mechanism of simvastatin on the renal protective effects of ADR nephropathy.
METHODS: Fifteen male Balb/c mice were randomly divided into normal control (NC), ADR nephropathy and simvastatin-treated ADR nephropathy (ADR-SIM) groups. ADR nephropathy was induced by a single intravenous injection of ADR into the tail vein. All mice were sacrificed at the end of the 7th week, with the blood, 24-h urine and kidneys collected. The levels of ox-LDL and total cholesterol in the serum, the serum CXCL16, ox-LDL and NF-κB expression were detected.
RESULTS: Compared with the NC group, the levels of serum total cholesterol and ox-LDL in the ADR and ADR-SIM groups were significantly higher, the level of serum albumin was significantly lower and the expression of CXCL16, ox-LDL and NF-κB in the renal tissue of ADR and ADR-SIM groups was significantly increased. Compared with the ADR group, the expressions of renal CXCL16, ox-LDL and NF-κB in the ADR-SIM group were significantly decreased. Levels of serum total cholesterol and ox-LDL were not significantly different between the two groups.
CONCLUSIONS: Simvastatin exerts a protective effect on renal function and structure in mice with ADR nephropathy. The beneficial effects of simvastatin might be related to the decreasing expression of CXCL16 in glomerular podocytes followed by the decreasing endocytosis of ox-LDL in podocytes and inhibition of NF-κB pathway activation.

Entities:  

Keywords:  Balb/c mice; CXCL16; adriamycin; nephropathy; ox-LDL; simvastatin

Mesh:

Substances:

Year:  2015        PMID: 26884839      PMCID: PMC4730052     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  35 in total

Review 1.  Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.

Authors:  Andreas Ludwig; Christian Hundhausen; Millard H Lambert; Neil Broadway; Robert C Andrews; D Mark Bickett; M Anthony Leesnitzer; J David Becherer
Journal:  Comb Chem High Throughput Screen       Date:  2005-03       Impact factor: 1.339

2.  Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway.

Authors:  Benedetta Bussolati; Maria Chiara Deregibus; Valentina Fonsato; Sophie Doublier; Tiziana Spatola; Simone Procida; Francesco Di Carlo; Giovanni Camussi
Journal:  J Am Soc Nephrol       Date:  2005-04-20       Impact factor: 10.121

3.  Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.

Authors:  G Tonolo; M Velussi; E Brocco; C Abaterusso; A Carraro; G Morgia; A Satta; R Faedda; A Abhyankar; H Luthman; R Nosadini
Journal:  Kidney Int       Date:  2006-05-17       Impact factor: 10.612

4.  Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis.

Authors:  Tianfu Wu; Chun Xie; Hong W Wang; Xin J Zhou; Noa Schwartz; Sergio Calixto; Meggan Mackay; Cynthia Aranow; Chaim Putterman; Chandra Mohan
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

5.  Rosuvastatin protects against podocyte apoptosis in vitro.

Authors:  Fionnuala C Cormack-Aboud; Paul T Brinkkoetter; Jeffrey W Pippin; Stuart J Shankland; Raghu V Durvasula
Journal:  Nephrol Dial Transplant       Date:  2008-09-27       Impact factor: 5.992

6.  Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis.

Authors:  Gabriela E Garcia; Luan D Truong; Ping Li; Ping Zhang; Richard J Johnson; Curtis B Wilson; Lili Feng
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 7.  Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis.

Authors:  Hyun Soon Lee; Chi Young Song
Journal:  Am J Nephrol       Date:  2008-08-08       Impact factor: 3.754

8.  CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.

Authors:  Paul Gutwein; Mohamed Sadek Abdel-Bakky; Anja Schramme; Kai Doberstein; Nicole Kämpfer-Kolb; Kerstin Amann; Ingeborg A Hauser; Nicholas Obermüller; Christine Bartel; Abdel-Aziz H Abdel-Aziz; El Sayed M El Sayed; Josef Pfeilschifter
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

9.  Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury.

Authors:  Daryl M Okamura; Jesús M López-Guisa; Katie Koelsch; Sarah Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2007-05-30

10.  Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats.

Authors:  Wei Zhang; Qiu Li; Lijia Wang; Xiqiang Yang
Journal:  Pediatr Nephrol       Date:  2008-09-13       Impact factor: 3.714

View more
  3 in total

1.  Early development of podocyte injury independently of hyperglycemia and elevations in arterial pressure in nondiabetic obese Dahl SS leptin receptor mutant rats.

Authors:  Kasi C McPherson; Lateia Taylor; Ashley C Johnson; Sean P Didion; Aron M Geurts; Michael R Garrett; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2016-07-27

2.  Behavior of Chemokine Receptor 6 (CXCR6) in Complex with CXCL16 Soluble form Chemokine by Molecular Dynamic Simulations: General Protein‒Ligand Interaction Model and 3D-QSAR Studies of Synthetic Antagonists.

Authors:  Giovanny Aguilera-Durán; Antonio Romo-Mancillas
Journal:  Life (Basel)       Date:  2021-04-15

3.  P2X7R antagonist protects against renal injury in mice with adriamycin nephropathy.

Authors:  Yanji Zhu; Min Liu; Wenlong Xun; Keliang Li; Xiangji Niu
Journal:  Exp Ther Med       Date:  2021-12-21       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.